Fig. 1: Overall survival in patients with severe COVID-19 pneumonia treated with ruxolitinib plus steroid (group A) compared to controls (Group B): Kaplan Meyer curves.
From: Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
The day of hospitalization was considered as time 0 in the y axis. Patients were censored at the time of live discharge from the hospital. No patient was lost at follow-up.
